Effect of the unfolded protein response and oxidative stress on mutagenesis in CSF3R: a model for evolution of severe congenital neutropenia to myelodysplastic syndrome/acute myeloid leukemia.
Animals
Congenital Bone Marrow Failure Syndromes
/ complications
Core Binding Factor Alpha 2 Subunit
/ drug effects
Endoplasmic Reticulum Stress
/ drug effects
GATA2 Deficiency
/ complications
Gene Expression Regulation, Leukemic
/ drug effects
Granulocyte Colony-Stimulating Factor
/ pharmacology
High-Throughput Nucleotide Sequencing
Humans
Mice
Mutagenesis
/ drug effects
Mutation
/ drug effects
Mutation Rate
Neutropenia
/ complications
Neutrophils
/ drug effects
Oxidative Stress
/ drug effects
Receptors, Colony-Stimulating Factor
/ administration & dosage
Signal Transduction
Unfolded Protein Response
/ drug effects
Journal
Mutagenesis
ISSN: 1464-3804
Titre abrégé: Mutagenesis
Pays: England
ID NLM: 8707812
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
17
12
2019
accepted:
21
09
2020
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
20
8
2021
Statut:
ppublish
Résumé
Severe congenital neutropenia (SCN) is a rare blood disorder characterised by abnormally low levels of circulating neutrophils. The most common recurrent mutations that cause SCN involve neutrophil elastase (ELANE). The treatment of choice for SCN is the administration of granulocyte-colony stimulating factor (G-CSF), which increases the neutrophil number and improves the survival and quality of life. Long-term survival is however linked to the development of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). About 70% of MDS/AML patients acquire nonsense mutations affecting the cytoplasmic domain of CSF3R (the G-CSF receptor). About 70% of SCN patients with AML harbour additional mutations in RUNX1. We hypothesised that this coding region of CSF3R constitutes a hotspot vulnerable to mutations resulting from excessive oxidative stress or endoplasmic reticulum (ER) stress. We used the murine Ba/F3 cell line to measure the effect of induced oxidative or ER stress on the mutation rate in our hypothesised hotspot of the exogenous human CSF3R, the corresponding region in the endogenous Csf3r, and Runx1. Ba/F3 cells transduced with the cDNA for partial C-terminal of CSF3R fused in-frame with a green fluorescent protein (GFP) tag were subjected to stress-inducing treatment for 30 days (~51 doubling times). The amplicon-based targeted deep sequencing data for days 15 and 30 samples show that although there was increased mutagenesis observed in all the three genes of interest (partial CSF3R, Csf3r and Runx1), there were more mutations in the GFP region compared with the partial CSF3R region. Our findings also indicate that there is no correlation between the stress-inducing chemical treatments and mutagenesis in Ba/F3 cells. Our data suggest that oxidative or ER stress induction does not promote genomic instability, affecting partial C-terminal of the transduced CSF3R, the endogenous Csf3R and the endogenous Runx1 in Ba/F3 cells that could account for these targets to being mutational hotspots. We conclude that other mechanisms to acquire mutations of CSF3R that help drive the evolution of SCN to MDS/AML.
Identifiants
pubmed: 33511998
pii: 6123387
doi: 10.1093/mutage/geaa027
pmc: PMC7846132
doi:
Substances chimiques
CSF3R protein, human
0
Core Binding Factor Alpha 2 Subunit
0
Csf3r protein, mouse
0
Receptors, Colony-Stimulating Factor
0
Runx1 protein, mouse
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-389Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL128173
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134880
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL136333
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA096520
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society.All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Genetics. 2016 Apr;202(4):1549-61
pubmed: 26883445
N Engl J Med. 1995 Aug 24;333(8):487-93
pubmed: 7542747
Blood. 1997 Apr 1;89(7):2369-75
pubmed: 9116280
Haematologica. 2005 Jan;90(1):45-53
pubmed: 15642668
J Leukoc Biol. 2017 Oct;102(4):1143-1151
pubmed: 28754797
Mol Biol Evol. 2005 Mar;22(3):650-8
pubmed: 15537806
Blood. 2007 Jan 1;109(1):93-9
pubmed: 16985178
Blood. 2014 Jan 23;123(4):562-9
pubmed: 24184683
Oncotarget. 2017 Feb 21;8(8):12596-12606
pubmed: 28208123
Blood. 2014 Apr 3;123(14):2229-37
pubmed: 24523240
Biochem Biophys Res Commun. 2009 Mar 13;380(3):449-53
pubmed: 19174151
Blood. 2012 May 31;119(22):5071-7
pubmed: 22371884
Br J Haematol. 2009 Nov;147(4):535-42
pubmed: 19775295
J Biol Chem. 2017 Feb 24;292(8):3496-3505
pubmed: 28073911
J Biol Chem. 2017 Dec 1;292(48):19656-19673
pubmed: 28972171
Food Chem. 2014 Jun 15;153:315-20
pubmed: 24491735
Annu Rev Immunol. 2011;29:399-413
pubmed: 21219176
N Engl J Med. 1989 Jun 15;320(24):1574-80
pubmed: 2471075
Leukemia. 2004 Sep;18(9):1553-5
pubmed: 15284863
Blood. 2005 May 1;105(9):3397-404
pubmed: 15657182
Blood. 2011 Mar 31;117(13):3539-47
pubmed: 21285438
J Neurosci. 2005 Nov 2;25(44):10321-35
pubmed: 16267240
Blood. 2006 Mar 1;107(5):1847-56
pubmed: 16282349
Ann Appl Probab. 2013;23(1):230-250
pubmed: 23471293
Blood. 2018 Jan 25;131(4):408-416
pubmed: 29092827
Blood. 2006 Jul 15;108(2):493-500
pubmed: 16551967
Hematology Am Soc Hematol Educ Program. 2009;:344-50
pubmed: 20008220
Nat Methods. 2013 May;10(5):407-9
pubmed: 23524392